SOCIETE GENERALE: DESCRIPTION OF THE SHARE BUYBACK PROGRAM

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
57
SOCIETE GENERALE: DESCRIPTION OF THE SHARE BUYBACK PROGRAM

12 May 2017

Des c r i p t ion o f the share buyback programme

Subject to the authorisation of the ordinary General Meeting dated 23 May 2017

This description is drawn up in accordance with the provisions of Articles 241-1 and 241-2 I of the General Regulation of the French Financial Markets Authority ( Autorité des marchés financiers ).

  1. D ate of the General Meeting called to authorise the share buyback programme

The authorisation for the Company to buy its own shares will be proposed to the ordinary General Meeting dated 23 May 2017.

  1. Breakdown by objectives of the securities held

As at 9 May 2017, the allocation of the shares held directly is as follows:

Cancellation 0
Allocation to employees and executive officers 6,865,176
Exercise of rights attached to securities 0
External growth 0
Liquidity agreement 44,600
  1. Purposes of the share buyback programme

Societe Generale contemplates renewing its authorisation to buy its own shares so it can:

- cancel them, in accordance with the terms of the authorisation of the combined General Meeting dated 18 May 2016 in its 21 st resolution, solely to offset the dilution resulting from the issuance of new shares as part of free shares plans or share capital increases reserved for employees;
- grant, cover and honour any free shares allocation plan, employee savings plan and any form of allocation for the benefit of employees and executive officers of the Company or affiliated companies under the conditions defined by the applicable legal and regulatory provisions;
- deliver shares upon the exercise of rights attached to securities giving access to the Company's share capital;
- hold and subsequently deliver shares as payment or exchange as part of Group's external growth transactions;
- allow an investment services provider to operate on the Company's shares as part of a liquidity agreement compliant with an ethical charter recognised by the French Financial Markets Authority ( Autorité des Marchés Financiers ).
  1. Maximum amount allocated to the share buyback programme, maximum number and characteristics of the securities, maximum purchase price

The resolution proposed to the General Meeting provides that Societe Generale could purchase its own shares for an amount of up to 5% of the share capital at the completion date of these purchases, within the legal limit of an amount of shares held representing 10% of the share capital after these buybacks.

As at 9 May 2017, without taking into account the shares already held, a theoretical maximum number of 40,385,676 shares could be purchased. Given the number of securities already held at this date and the possibility to hold an amount of shares representing up to 10% of the share capital, the Company could purchase up to 40,385,676 shares.

The maximum purchase price would be set at EUR 75 per share, i.e. a potential maximum amount allocated to the programme of EUR 3,028,925,700.

The Board of Directors will ensure that the implementation of the buybacks is conducted in compliance with the prudential requirements as set by the regulations.

  1. Duration of share buyback programme

It is proposed to the ordinary General Meeting dated 23 May 2017 to set the duration of the authorisation for the Company to buy and sell its own shares at 18 months from the date of the General Meeting.

Attachments:

http://www.globenewswire.com/NewsRoom/Attachm...2b843ce8e2

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 15

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

ANI Pharmaceuticals Plans to Shine at Biotech Conference

Updated Category News Views 257

ANI Pharmaceuticals Set for Key Presentation at Biotech Conference ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is gearing up to showcase its advancements at the Guggenheim Biotech Conference. On an exciting date, Nikhil Lalwani, the Company’s President and CEO, along with Stephen Carey, the CFO, will host a fireside chat to discuss the latest developments and future plans...

Continue Reading
New Shuttle Drives Economic Recovery on O'ahu

Updated Category News Views 26

Reviving the North Shore Economy, One Shuttle Ride at a Time Not every day do you see a $5 investment with such community punch. On June 29, a new bus service launches, whisking folks from Waik?k? and Ko Olina to O?ahu’s North Shore. But this ain't just another tourist bus ride—it's a lifeline for local businesses hit hard by March's kona low storms. Connecting...

Continue Reading
Virginia Cancer Specialists Expands Services with New Center

Updated Category News Views 21

Virginia Cancer Specialists Expands its Reach with a New Center Virginia Cancer Specialists, a leading private cancer practice in the region, has announced the opening of their newly expanded cancer center. This important development aims to enhance patient care and provide access to the latest cancer treatments. The expansion not only signifies growth but also a...

Continue Reading
Key Financial Dates for TCM Group A/S's Upcoming Year

Updated Category News Views 167

Important Financial Calendar for TCM Group A/S TCM Group A/S is a significant player in the kitchen and furniture manufacturing industry. As the year approaches its end, the company has established key dates for reporting and annual meetings, signaling to shareholders and stakeholders the importance of staying informed. Scheduled Report Releases and Meetings The Board of...

Continue Reading
Unexpected Chicago PMI Falls Raises Concerns for Manufacturing

Updated Category News Views 323

Understanding the Recent Chicago PMI Decline Recently, the Chicago Purchasing Managers' Index (PMI) reported a surprising score of 36.9, highlighting ongoing challenges in the manufacturing sector within the region. This score is a clear indication that the manufacturing landscape in Chicago is experiencing significant contraction, a worrisome sign for the local and...

Continue Reading